The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta‐Analysis Study

We identified 22 active comparators; "tofacitinib 10 mg twice daily" was ranked most efficacious in terms of 16 to 24-week mean change in NAPSI (SUCRA = 99.71%)-while "ixekizumab 160 mg at week 0 followed by 80 mg every 4 weeks" was ranked most efficacious (SUCRA = 95.67%) for proportion attaining PGA-f of 0 or 1 (i.e., outcome 2). Our analyses produced comparative evidence for the relative efficacy of monotherapies with various agents, including biologics and non-biologics. Our findings would guide clinical decision-making.